...chronic disease management. Some money is earmarked for life sciences programs in surgery, pathology and immunology.dMed... ...via $100M roundFidelity Management & Research Co. led a $100 million series C round in dMed... ...$10. The company closed up $6.71 (67%) to $16.71 on the day.
BC Staff
Setrusumab (BPS804, BPS-804)
Ultragenyx
Mereo BioPharma
Verily
dMed...
...the pandemic today can be built into a long-term China strategy for tomorrow.” Lingshi Tan, dMed... ...CEO at dMed. Signed commentaries do not necessarily reflect the views of BioCentury.
Lingshi Tan, dMed Global
dMed...
...stopped in most hospitals,” said Yan Yi, head of clinical and commercial operations at CRO dMed... ...such as prioritizing the most urgent trials to address current disruptions. Digital solutions Zhang and dMed's... ...are in better shape to manage the current situation.” George Baeder, dMed According to Baeder, dMed...
...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed... ...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed... ...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
...a 12% discount from Tuesday’s close of $6.22. Vivo leads dMed's $50M series B Shanghai-based dMed... ...will allow the CRO to expand its clinical operations and information technology infrastructure. In June, dMed... ...appointed Thomas Eldered as chair.
Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor
Ascentage Pharma Group International
dMed...
...chronic disease management. Some money is earmarked for life sciences programs in surgery, pathology and immunology.dMed... ...via $100M roundFidelity Management & Research Co. led a $100 million series C round in dMed... ...$10. The company closed up $6.71 (67%) to $16.71 on the day.
BC Staff
Setrusumab (BPS804, BPS-804)
Ultragenyx
Mereo BioPharma
Verily
dMed...
...the pandemic today can be built into a long-term China strategy for tomorrow.” Lingshi Tan, dMed... ...CEO at dMed. Signed commentaries do not necessarily reflect the views of BioCentury.
Lingshi Tan, dMed Global
dMed...
...stopped in most hospitals,” said Yan Yi, head of clinical and commercial operations at CRO dMed... ...such as prioritizing the most urgent trials to address current disruptions. Digital solutions Zhang and dMed's... ...are in better shape to manage the current situation.” George Baeder, dMed According to Baeder, dMed...
...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed... ...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed... ...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
...a 12% discount from Tuesday’s close of $6.22. Vivo leads dMed's $50M series B Shanghai-based dMed... ...will allow the CRO to expand its clinical operations and information technology infrastructure. In June, dMed... ...appointed Thomas Eldered as chair.
Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor
Ascentage Pharma Group International
dMed...
